O n Thursday, BMO Capital Markets updated its outlook on Travelers Companies Inc (NYSE:TRV), with analyst Michael Zaremski increasing the price target to $297 from the previous $275. The firm has ...

Bank of Montreal’s veteran oil and gas analyst is making the case for a four-way mega merger in Western Canada’s Montney Formation, arguing such a deal would boost scale and broaden investor appeal.

(Bloomberg) -- Bank of Montreal and Bank of Nova Scotia kicked off Canadian bank earnings season with strong results from their capital-markets divisions amid an increase in trading activity.

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage ...

BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued ...

The S&P 500 has never lost ground in the back half of the year after advancing between 10% and 15% in the first six months, according to BMO Capital Markets, citing data since 1950. The Montreal ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of ...

It operates through Canadian P&C, U.S P&C, BMO Wealth Management, and BMO Capital Markets segments. The company’s personal banking products and services include deposits, mortgages, home lending ...

BMO Capital raised the firm’s price target on Okta (OKTA) to $130 from $105 and keeps a Market Perform rating on the shares. The firm had been ...

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the shares. The firm cites the company’s VERITAC-2 data ...

On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...